After taking over as chief executive of AstraZeneca in 2012, Pascal Soriot sent a team to a global life sciences conference to look for potential drug discovery partners. There were few interested takers. “They were a bit of a joke,” says one veteran investor who attended the event. “They w
```
Members Only

Login or create an account to continue

This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.

New to BusinessDay? Register now and start reading.

```

Join BusinessDay whatsapp Channel, to stay up to date

Open In Whatsapp